Cargando…
Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
AIMS: To evaluate the pharmacokinetics and pharmacodynamics of basal insulin glargine with mealtime insulin glulisine or twice daily 75/25 premixed neutral protamine insulin lispro and insulin lispro in individuals with type 1 diabetes during three standardized meals over a 24 hour duration and comp...
Autores principales: | Lamos, Elizabeth Mary, Younk, Lisa M., Tate, Donna B., Davis, Stephen N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680437/ https://www.ncbi.nlm.nih.gov/pubmed/29159123 http://dx.doi.org/10.1016/j.jcte.2015.12.002 |
Ejemplares similares
-
PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022) -
Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019) -
Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016) -
Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020) -
Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)